The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Changing paradigms in the systemic treatment of advanced cervical cancer
Open accessAbstract
Despite availability of primary and secondary prevention measures, cervical cancer persists as one of the most common cancers among women around the world. While early stage disease can be cured with radical and even fertility-sparing surgery, patients with metastatic and recurrent cervical cancer have poor prognosis with historically limited treatment options and incurable disease. Significant advances in cervical cancer treatment have emerged as the result clinical trials seeking to determine the best therapy to prolong overall and progression-free survival. Most recently, trials involving angiogenesis blockade in addition to standard chemotherapy have demonstrated improved overall and progression free survival. This review serves to highlight pivotal trials in chemotherapy development for advanced, metastatic and recurrent cervical cancer including the paradigm-shifting work demonstrating increased overall survival with angiogenesis blockade.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
Ferrara, N., Hillan, K. J., Gerber, H.-P., & Novotny, W. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1381 · Cited by 2,625 · cited 1×
“Ferrara et al developed bevacizumab, a humanized anti-VEGF monoclonal antibody that bound with an affinity comparable to that of the original antibody.(24) Bevacizumab was the first angiogenesis inhibitor to be approved by the Food and Drug Administration for cancer treatment.”
Cited by
Chung, H. C., Ros, W., Delord, J.-P., Perets, R., Italiano, A., Shapira-Frommer, R., Manzuk, L., Piha-Paul, S. A., Xu, L., Zeigenfuss, S., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01265 · Cited by 1,069
Frenel, J.-S., Le Tourneau, C., O’Neil, B., Ott, P. A., Piha-Paul, S. A., Gomez-Roca, C., van Brummelen, E. M. J., Rugo, H. S., Thomas, S., Saraf, S., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.5471 · Cited by 531
Cervical Cancer Immunotherapy: Facts and Hopes
Ferrall, L., Lin, K. Y., Roden, R. B. S., Hung, C.-F., & Wu, T.-C. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2833 · Cited by 395
Jim, M. A., Pinheiro, P. S., Carreira, H., Espey, D. K., Wiggins, C. L., & Weir, H. K. (2017) · Cancer · doi:10.1002/cncr.30881 · Cited by 300
Application of Dendrimers for the Treatment of Infectious Diseases
Mhlwatika, Z., & Aderibigbe, B. A. (2018) · Molecules · doi:10.3390/molecules23092205 · Cited by 97
Metadata
- Authors
- Pfaendler, K. S., & Tewari, K. S.
- Venue
- American Journal of Obstetrics and Gynecology
- Publisher
- Elsevier BV
- Published
- 2016-01
- Volume
- 214
- Issue
- 1
- Pages
- 22-30
- ISSN
- 0002-9378 (ISSN-L)
- OpenAlex
- W1857980043
- Cited by
- 221
- References
- 1
- FWCI
- 13.29
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Changing paradigms in the systemic treatment of advanced cervical cancer. https://app.cochat.ai/papers/10.1016/j.ajog.2015.07.022
- The paper
- Pfaendler, K. S., & Tewari, K. S. (2016). Changing paradigms in the systemic treatment of advanced cervical cancer. American Journal of Obstetrics and Gynecology. https://doi.org/10.1016/j.ajog.2015.07.022
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.